-
Heavy document released, Chinese medicine enterprises "going out" and speeding up
Time of Update: 2022-04-15
Vigorously develop TCM service trade and build a high-quality national TCM service export base; promote the overseas localization of TCM, promote industrial collaboration and international trade; encourage the development of "Internet + TCM trade"; gradually improve the "going out" of TCM Relevant measures, carry out policy research on the overseas market of traditional Chinese medicine, and help traditional Chinese medicine enterprises to "go global" .
-
Over 1 billion anti-epileptic drug varieties, usher in another over-reviewed pharmaceutical company!
Time of Update: 2022-04-15
com, in 2019, the terminal sales of sodium valproate in China's public medical institutions exceeded 2 billion yuan, and injections accounted for more than 60% of the market share .
-
A large number of pharmaceutical companies have intensively disclosed operating data from January to February, focusing on CXO, traditional Chinese medicine and other fields
Time of Update: 2022-04-15
A number of pharmaceutical companies have performed well and are expected to achieve rapid growth in performance from January to February, including WuXi AppTec, Huitai Medical, Zuoli Pharmaceutical, and Bloomage Bio .
-
"Dry goods" are ready, come to the video conference on April 15th to talk about solid and hazardous waste detection and identification technology
Time of Update: 2022-04-15
Break through the technical blocking points of solid and hazardous waste identification, conduct discussions based on the actual engineering environment, and seek high-quality development of the industry in the future!
-
In the annual report dividend season, many pharmaceutical companies distributed cash dividends exceeding 10 yuan for every 10 shares!
Time of Update: 2022-04-15
Among them, many pharmaceutical companies including Yiqiao Shenzhou, Yunnan Baiyao, Livzon Group, Huitai Medical and other pharmaceutical companies distributed cash dividends exceeding 10 yuan per 10 shares .
The 2021 annual report shows that the company achieved a total operating income of 965 million yuan, a year-on-year decrease of 39.
-
The innovation of local pharmaceutical companies is accelerating, and the situation is becoming more diversified!
Time of Update: 2022-04-15
It is reported that in recent years Bio-Tech, Henlius, and Innovent have all authorized overseas licenses to commercialize new drugs, and have seized both domestic and overseas markets .
-
1957 batches of Chinese herbal decoction pieces were sampled, and 32 batches were non-compliant!
Time of Update: 2022-04-15
In addition, the main problems found in the special sampling inspection of Chinese herbal medicines include: the substitution and doping of counterfeit products; the problem of excessive residues of exogenous harmful substances; the problem of irregular harvesting and processing .
According to the industry, the high-quality development of Chinese herbal decoction pieces has become the general trend .
-
There are nearly 5,000 varieties of traditional Chinese medicine formula granules registered in the country, and these pharmaceutical companies have more than 100
Time of Update: 2022-04-15
Among them, a number of manufacturers have more than 100 registered varieties, including China Traditional Chinese Medicine, Tianjin Hongri, Hunan Xinhui, China Resources Sanjiu, Sichuan New Green, etc.
Judging from the number of varieties of traditional Chinese medicine formula granules filed, both companies have more than 200, 302 and 219 respectively .
-
The dry eye drug market of over 40 billion yuan is attracting many pharmaceutical companies to enter the market
Time of Update: 2022-04-15
Among them, the blockbuster ophthalmic product cyclosporine A eye gel has completed a large-scale clinical trial in China, involving 644 patients in 41 centers .
S. Phase II Clinical Trial for Dry Eye On March 23, Dimensional Bio announced that its self-developed innovative drug VVN001 achieved positive results in U.
-
3 pharmaceutical companies have reviewed 7 varieties, and 2 varieties have been subsidized by 1.5 million yuan each!
Time of Update: 2022-04-15
For example, according to recent news, Nantong Lianya Pharmaceutical, Jiangsu Wangao Pharmaceutical, and Jiangsu Chenpai Pharmaceutical have a total of 7 generic drugs that have passed the consistency evaluation, and 4 of them have received funding of 5 million yuan .
-
The heavyweight domestic PD-1 listing application was accepted by the EMA, accelerating the process of globalization
Time of Update: 2022-04-15
[Pharmaceutical Industry News] Following the official acceptance of the new drug marketing application (BLA) of BeiGene's PD-1 monoclonal antibody Baizean by the US FDA in September 2021, the product has recently received a marketing authorization application and was approved by the European Medicines Agency The good news accepted by (EMA) means that Baizean is accelerating the process of globalization .
-
Good news!
Time of Update: 2022-04-15
Cefdizazine sodium is a third-generation cephalosporin, which is mainly used clinically for pneumonia, bronchitis, pharyngitis, tonsillitis, pyelonephritis, urinary tract infection, and gonococcal urethritis caused by sensitive bacteria such as Streptococcus and pneumococcus.
-
Technology is advancing rapidly, and the pharmaceutical industry is pushing for intelligent transformation
Time of Update: 2022-04-15
According to reports, in 2021, at the same time as the secondary research and development of varieties, Benxi Sanyao will invest 40 million yuan to carry out intelligent transformation in the production field .
-
PARP inhibitors - Can you see the hidden corners of the new anti-cancer trend?
Time of Update: 2022-03-10
Like all teenage heroes, when Olaparib first appeared and filled the global market expectations, the first Waterloo also arrived as scheduled in 2011: Phase II clinical results published in the New England Journal of Medicine in patients with platinum-sensitive ovarian cancer Among them, olaparib failed to prolong overall survival [3] .
-
Jingfeng Pharmaceutical's subsidiary flurbiprofen axetil injection obtained drug registration approval
Time of Update: 2022-03-10
On December 23, Jingfeng Pharmaceutical announced that its subsidiary, Pude Kangli, has obtained the drug registration approval for the chemical drug "flurbiprofen axetil injection" approved and issued by the State Food and Drug Administration .
Flurbiprofen axetil injection is a non-steroidal anti-inflammatory analgesic, clinically used for postoperative analgesia and cancer .
-
Kintor's new crown drug Prokluamide US Phase III clinical trial failed to reach statistical significance
Time of Update: 2022-03-10
On the evening of December 27, the Hong Kong stock market of Kintor Pharmaceuticals issued an announcement announcing the progress of the Phase III clinical trial of proclutamide in the treatment of non-hospitalized patients with mild to moderate disease .
-
Policy plus code!
Time of Update: 2022-03-10
The proportion of characteristic APIs with high technical barriers and high gross profit margins is relatively low, and the early domestic API industry chain advantages More concentrated on intermediates and some bulk APIs, and high value-added specialty APIs are more controlled by European, American and Indian companies .
-
Importance of reverse screening for new drug discovery
Time of Update: 2022-03-10
However, this kind of so-called high-throughput screening is also relatively rough, and often occurs similar to the palladium-free catalyzed coupling reaction, which requires reverse screening to eliminate false positive hits .
-
Ten billion varieties fell to the altar!
Time of Update: 2022-03-10
com China's public medical institutions terminal competition patternAmong the top 10 products, atorvastatin calcium tablets and rosuvastatin calcium tablets have long been the top brand products, and the cholesterol absorption inhibitor ezetimibe has risen from the tenth place in 2018 to the third place in the first half of 2021.
-
Gout patients are so serious after 5 years if they don't take medicine?
Time of Update: 2022-03-10
Allopurinol, febuxostat, or benzbromarone are recommended as first-line urate-lowering drugs in gout patients .
Allopurinol is recommended as the first-line drug for lowering uric acid in patients with hyperuricemia and gout.
